摘要目的：观察重组人促红细胞生成素（rHu-EPO）治疗原发性脑干损伤的有效性和安全性。方法收集2010年7月至2013年7月山东省聊城市人民医院神经外科收治的原发性脑干损伤患者60例。将其随机分为 EPO 治疗组与对照组。两组患者均给予常规治疗，治疗组在常规治疗的基础上于规定时间皮下注射 rHu-EPO 6000 U，共5次，疗程为2周；对照组给予安慰剂处理。两组患者治疗后2周进行 NIHSS 评分、3个月进行 GOS 评分。同期监测患者的血压、血红蛋白等指标。结果治疗2周后，与对照组相比，EPO 治疗组 NIHSS 评分较对照组降低明显[（11.37±7.78）、（19.41±8.26）分]，两组比较差异有统计学意义（P =0.019）；3个月后两组患者的预后比较差异有统计学意义（ Z =-2.367，P=0.009）；两组患者血压、血红蛋白未出现明显异常。结论 rHu-EPO 具有一定的神经保护作用，可能对治疗原发性脑干损伤有效。

abstractsObjective To observe the short-term curative effect and safety of recombinant human erythropoietin(rHu-EPO)on patients with primary brain stem injury. Methods Sixty patients with primary brain stem injury were recruited at Liaocheng People' Hospital from July 2010 to July 2013. All cases were randomly divided into EPO group and control group. The patients in EPO group were injected subcutaneous with rHu-EPO five times at dose of 6 000 U,while patients in the control group were treated with placebo in 2 weeks. All other conventional treatments were the same. NIHSS score and GOS score were evaluated in two weeks and three months respectively. Moreover,blood pressure and hemoglobin were also measured. Results NIHSS score in EPO group was 11. 37 ± 7. 78,significant higher than that of control group after two weeks(19. 41 ± 8. 26,P = 0. 019). GOS score in EPO group was also significant differences in two groups after three months (Z = - 2. 367,P = 0. 009 ). However,no significant difference was observed in the followed-up blood tests. Conclusion Recombinant human erythropoietin could be the exact nerve protective effect,and might be an effective therapy for patients with primary brain stem injury.